Aardvark Therapeutics (NASDAQ:AARD) shareholders approved all three proposals presented at the company’s 2026 Annual Meeting of Stockholders, including the election of two Class I directors, the appointment of BDO USA as independent auditor and the repricing of certain stock options.
The virtual meeting was called to order by Chief Executive Officer Tien Lee, who also served as chairman. Chief Financial Officer Nelson Sun acted as secretary. Lee said the board had appointed James R. Alden of American Election Services, LLC, as inspector of election.
Director Elections Approved
Shareholders elected Jeffrey Chi, Ph.D., and Victor Tong Jr. as Class I directors. Each will serve until the company’s 2029 Annual Meeting of Stockholders or until a successor is elected and qualified.
Lee said both nominees were current directors and had been recommended by Aardvark’s board. No advance notices of shareholder director nominations were received, and the nominations were subsequently closed.
Auditor Ratification and Option Repricing
Shareholders also ratified the audit committee’s appointment of BDO USA as Aardvark’s independent registered public accounting firm and independent auditor for the fiscal year ending Dec. 31, 2026.
In addition, shareholders approved the repricing of certain stock options granted under the company’s 2017 Equity Incentive Plan, as amended; its 2025 Equity Incentive Plan; and its 2025 Inducement Equity Incentive Plan.
The meeting agenda contained no additional shareholder proposals. Voting was conducted by proxy and electronic ballot, with each holder of common stock entitled to one vote per share held as of the June 18 record date.
Polls closed at 9:07 a.m. Pacific Time. Sun said the results announced during the meeting were preliminary because the complete share-vote figures were not yet available. The inspector of election will provide a written final report, and Aardvark said it expects to publish the final vote tally in a Current Report on Form 8-K filed with the Securities and Exchange Commission on or before Aug. 20, 2026.
Lee adjourned the meeting after noting that the company had not received questions concerning the agenda items.
About Aardvark Therapeutics (NASDAQ:AARD)
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.
